Summary
2.59 0.05(1.77%)11/29/2024
Alector Inc (ALEC)
ALEC reported last earnings on 2024-11-06 after the market. An EPS of $-0.43 was observed compared to an estimated EPS of $-0.53, resulting in a surprise value of $0.10. A revenue of $15 million was observed compared to an estimated revenue of $16 million, resulting in a surprise value of $-1 Million.
Alector Inc (ALEC)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.77 | -34.26 | -48.86 | -50.48 | -48.20 | -52.30 | -86.11 | -85.61 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Earnings
Fundamental Ratings
| Category | Rating |
| Main Rating | C- |
| Recommended Rating | Strong Sell |
| DCF | Strong Sell |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Neutral |
| P/E | Strong Sell |
| P/B | Sell |
| Trading Data | ||
| Close | 2.59 | |
| Open | 2.55 | |
| High | 2.69 | |
| Low | 2.41 | |
| Volume | 2,570,046 | |
| Change | 0.05 | |
| Change % | 1.77 | |
| Avg Volume (20 Days) | 1,630,120 | |
| Volume/Avg Volume (20 Days) Ratio | 1.58 | |
| 52 Week Range | 2.37 - 8.90 | |
| Price vs 52 Week High | -70.90% | |
| Price vs 52 Week Low | 9.28% | |
| Range | 1.57 | |
| Gap Up/Down | -0.08 | |
Fundamentals | ||
| Market Capitalization (Mln) | 448 | |
| EBIDTA | -80,913,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 45.14 | |
| Book Value | 4.1340 | |
| Earnings Per Share | -0.4200 | |
| EPS Estimate Current Quarter | 2.0900 | |
| EPS Estimate Next Quarter | -0.5700 | |
| EPS Estimate Current Year | 0.2600 | |
| EPS Estimate Next Year | 0.4900 | |
| Diluted EPS (TTM) | -0.4200 | |
| Revenues | ||
| Profit Marging | -0.1662 | |
| Operating Marging (TTM) | -0.1725 | |
| Return on asset (TTM) | -0.0308 | |
| Return on equity (TTM) | -0.1018 | |
| Revenue TTM | 197,944,000 | |
| Revenue per share TTM | 2.4810 | |
| Quarterly Revenue Growth (YOY) | 29.8970 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -135,771,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 714.2857 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 5.2193 | |
| Revenue Enterprise Value | 5.1727 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 81,276,096 | |
| Shares Float | 54,489,934 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 12.14 | |
| Institutions (%) | 81.57 | |
11/27 10:46 EST - zacks.com
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study
Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.
11/26 10:29 EST - benzinga.com
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD).
11/25 16:05 EST - globenewswire.com
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial...
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial...
11/14 16:05 EST - globenewswire.com
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50...
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50...
11/06 18:50 EST - zacks.com
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.
11/06 16:05 EST - globenewswire.com
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024
10/23 17:28 EST - businesswire.com
Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.
Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.
08/29 07:00 EST - globenewswire.com
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:
08/08 23:53 EST - seekingalpha.com
Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research...
Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript
Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research...
08/07 19:15 EST - zacks.com
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago.
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago.
08/07 16:05 EST - globenewswire.com
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024
07/31 16:05 EST - globenewswire.com
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
07/28 08:05 EST - globenewswire.com
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that...
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that...
07/23 07:00 EST - globenewswire.com
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association...
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association...
06/10 07:00 EST - globenewswire.com
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
05/08 19:26 EST - zacks.com
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.55 per share a year ago.
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
Alector (ALEC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.55 per share a year ago.
04/25 11:05 EST - zacks.com
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02/27 23:23 EST - seekingalpha.com
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript
Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript